Methanex Co. (NASDAQ:MEOH) (TSE:MX) has received an average rating of “Buy” from the fifteen ratings firms that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, six have given a buy rating and two have issued a strong buy rating on the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $68.95.
Several research analysts have recently weighed in on the stock. Zacks Investment Research upgraded shares of Methanex from....More>>>
Both Under Armourand Fitbitstocks are trading at dramatically lower prices than they were just a few years ago. But shares are outperforming the market so far in 2018 as investors have grown less pessimistic about their businesses.
So which of these rebounding stocks makes the better buy today?
Let’s take a closer look.
Under Armour vs. Fitbit
Company Market Cap Sales Growth Gross Profit Margin Price-to-Sales Ratio 52-Week Performance
Under Armour (NYSE:UA) (NYSE:UAA)
Late last month, Microsoft Corporation (NASDAQ:MSFT) announced a major reorganization that included, among other things, a stepped-up focus on Internet of Things (IoT).
Shortly after that, the company announced it was committing $5 billion to the research and developing of IoT technologies — news that MSFT stock owners cheered again, even without knowing exactly what that meant at the time.
By and large, it’s still not exactly clear what Microsoft aims to “do” as it dives deeper into the Internet of Things fray. Maybe it won’t be clear until the restructuring....More>>>
When Julia Di first told her family she wanted to study engineering, her mother begged her to reconsider.
“She flat-out said, ‘Julia, being an engineer is really hard. It’s a man’s world. You’re going to have a lot of struggles if you choose this route,'” Di remembers.
Di is a 20-year-old student studying electrical engineering and computer science at Columbia University, set to graduate in 2018.
She’s been paying attention to all the news: the Google memo, harassment at Uber and more. She says that while it hasn’t changed....More>>>
Pick a small-cap biotech company, any small-cap biotech company, and you could be picking the winning lottery ticket if its cutting-edge research pans out. And if it doesn’t? Well, then you could end up like StemCells (STEM), which reported lackluster trial data and announced that it would be winding down. Maxim’s Jason Kolbert and Jason McCarthy explain:
Surprising news came this morning that StemCells will terminate the companys Phase II Pathway Study in spinal cord injury (SCI). The decision follows a review of data from the Interim Analysis Data Monitoring Committee. The....More>>>